Rapport Therapeutics (RAPP) Equity Average (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Equity Average data on file, last reported at $478.1 million in Q1 2026.

• Equity Average for Q1 2026 came in at $478.1 million, up 61.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $478.1 million (up 61.72% YoY), and the FY2025 annual result was $395.0 million, up 182.38% from the prior year.
• Equity Average retreated to $478.1 million in Q1 2026 per RAPP's latest filing, from $498.1 million in the prior quarter.
• Over five years, Equity Average peaked at $498.1 million in Q4 2025 and troughed at -$32.6 million in Q1 2024.
• A 4-year average of $242.2 million and a median of $295.6 million in 2025 frame the typical range for Equity Average.
• The sharpest annual moves came in 2024 and 2025: Equity Average surged 3026.83% in 2024, then climbed 17.44% in 2025.
• A 4-year view of Equity Average shows it stood at -$19.4 million in 2023, then surged by 1722.0% to $314.3 million in 2024, then soared by 58.51% to $498.1 million in 2025, then fell by 4.03% to $478.1 million in 2026.
• Business Quant data shows RAPP's Equity Average at $478.1 million in Q1 2026, $498.1 million in Q4 2025, and $387.6 million in Q3 2025.